Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
Cumulative evidence has suggested that genetic predisposition contributes to susceptibility to systemic lupus erythematosus (SLE). The search of SLE susceptibility genes has involved mainly testing functionally relevant genes as candidates in population-based association studies. Because positive association may occur as an artifact of population admixture, the addition of linkage analysis offers more compelling evidence for susceptibility genes based on physical locations. We previously reported evidence for linkage of SLE to a 15 cM region on chromosome 1q41-q42. Within this interval, there are several candidate genes including PARP and HLX1 which encode poly(ADP-ribose)polymerase (PARP) and a homeo box protein, respectively. Using a family-based association test, we have recently observed evidence for association of PARP (but not HLX1) alleles with SLE in 124 families containing offspring afflicted with SLE (p= 0.00008 by the multi-allele transmission-disequilibrium test), and thus suggesting a role of PARP in SLE susceptibility. Previously PARP was also implicated in SLE based on its lower than normal range of activity in SLE patients, its intermediate range of activity in unaffected family members of SLE patients, and its decreased mRNA levels in SLE patients. Abnormal DNA repair has been reported in SLE patients. These multiple lines of evidence has led us to hypothesize that PARP is an SLE susceptibility gene. PARP is activated by DNA strand breaks which transfers ADP-ribose residues from NAD to nuclear proteins involved in various chromatin functions including DNA repair. It is specifically cleaved by caspase-3 induced during apoptosis. This proposal tests whether allelic variation of PARP causes functional variation to account for heritable differences in SLE susceptibility primarily using EBV-transformed cell lines from SLE patients and their family members. This PARP polymorphism is a simple sequence repeat (SSR) within the promoter, and thus may affect levels of mRNA and protein expression. It is also likely that this polymorphism represents a marker in linkage disequilibrium with other polymorphism(s) influencing PARP activity. We propose to 1) study PARP expression in individuals homozygous for the SLE-associated allele and individuals with other alleles by comparing levels of protein, mRNA, promoter activity, and post-translational modification, 2) characterize allelic variation of PARP activity and the related DNA repair, 3) study allelic variation of apoptotic cleavage of PARP upon induction, and 4) define the structural basis of any observed variation of PARP. In summary, our proposed study will assess whether allelic variation of PARP causes quantitative variation in expression, enzyme activity, sensitivity as a substrate, and DNA repair which may contribute to SLE susceptibility. Results from this study will support (or refute) a role of PARP in SLE susceptibility.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
092530369
UEI
RN64EPNH8JC6
Project Start Date
30-September-1999
Project End Date
29-September-2001
Budget Start Date
30-September-1999
Budget End Date
29-September-2001
Project Funding Information for 1999
Total Funding
$100,000
Direct Costs
$70,926
Indirect Costs
$29,074
Year
Funding IC
FY Total Cost by IC
1999
NIH Office of the Director
$100,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI045916-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI045916-01
Patents
No Patents information available for 1R21AI045916-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI045916-01
Clinical Studies
No Clinical Studies information available for 1R21AI045916-01
News and More
Related News Releases
No news release information available for 1R21AI045916-01
History
No Historical information available for 1R21AI045916-01
Similar Projects
No Similar Projects information available for 1R21AI045916-01